PepGen (PEPG) Cash from Financing Activities (2021 - 2026)
PepGen (PEPG) posted Cash from Financing Activities of $1.5 million for Q1 2026, up 987.72% sequentially from -$171000.0 in Q4 2025.
PepGen (PEPG) Cash from Financing Activities (2021 - 2026) Analysis & Trends
PepGen has reported Cash from Financing Activities for 6 years, with the latest figure at $1.5 million in Q1 2026.
- Quarterly Cash from Financing Activities changed N/A year-over-year to $1.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $109.5 million (up 6044.61% YoY) and the FY2025 annual result came in at $108.0 million, up 21.67% from the prior year.
- Cash from Financing Activities advanced to $1.5 million in Q1 2026 per PEPG's latest filing, from -$171000.0 in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $113.4 million in Q2 2022 and troughed at -$1.4 million in Q3 2022.
- A 5-year average of $19.4 million and a median of $129000.0 in 2023 frame the typical range for Cash from Financing Activities.
- The sharpest annual moves came in 2024 and 2025: Cash from Financing Activities jumped 66797.69% in 2024, then plunged 233.59% in 2025.
- Over 5 years, Cash from Financing Activities stood at $217000.0 in 2022, then tumbled by 88.02% to $26000.0 in 2023, then jumped by 392.31% to $128000.0 in 2024, then slumped by 233.59% to -$171000.0 in 2025, then soared by 987.72% to $1.5 million in 2026.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered $1.5 million, -$171000.0, and $108.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.42 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -6.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -207,909.22 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -273.15 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 36.24 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 27.18 Mn |
| 10 | PepGen | 207.09 Mn | 207.09 Mn | - | -65,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -65,000.00 |
| Jun 30, 2026 | -65,000.00 |
| Mar 31, 2026 | 1.52 Mn |
| Mar 31, 2026 | 1.52 Mn |
| Dec 31, 2025 | -171,000.00 |
| Dec 31, 2025 | -171,000.00 |
| Sep 30, 2025 | 108.05 Mn |
| Sep 30, 2025 | 108.05 Mn |
| Jun 30, 2025 | 98,000.00 |
| Jun 30, 2025 | 98,000.00 |
| Dec 31, 2024 | 128,000.00 |
| Dec 31, 2024 | 128,000.00 |
| Sep 30, 2024 | 327,000.00 |
| Sep 30, 2024 | 327,000.00 |
| Jun 30, 2024 | 1.33 Mn |
| Jun 30, 2024 | 1.33 Mn |
| Mar 31, 2024 | 86.97 Mn |
| Mar 31, 2024 | 86.97 Mn |
| Dec 31, 2023 | 26,000.00 |
| Dec 31, 2023 | 26,000.00 |